Is Hexo Corp (TSX:HEXO) a Buy After Earnings?

Hexo Corp’s (TSX:HEXO) latest financial results were a bit of a flop. Is this an opportunity for investors?

| More on:
question marks written reminders tickets

Image source: Getty Images

Much of the investing world holds its breath whenever one of the top marijuana companies reports its quarterly earnings. Given that we’re still in the early stages of the development of the industry, it’s critical to pay attention to how the market develops and which companies are making a major impact. The latest major pot company to report its quarterly earnings was Hexo Corp (TSX:HEXO). Let’s see how the Quebec-based company did.

Hexo misses on net revenue expectations

Hexo’s gross cannabis revenue was up a whopping 1,285% year over year. This much isn’t particularly surprising; marijuana companies have been racking up sales recently, especially since recreational uses were legalized. However, Hexo’s net revenue, which was about $13 million, declined by about 3% quarter over quarter, falling short of analyst expectations by about $2 million.

Naturally, this didn’t bode well for investors. The firm’s stock fell sharply (by as much as 8%) on the day its earnings were released. Note that Hexo actually beat on earnings estimates, reporting a net loss of $0.04 per share as opposed to the consensus estimates of $0.05 per share.

Increasing production capacity

Hexo is projected to become one of the dozen (or so) cannabis companies in Canada with a production capacity above 100,000 kilograms per year at its peak. The firm will be able to produce in excess of 150,000 kilograms per year. During its latest reported quarter, Hexo produced 9,804 kilograms of dried cannabis, an increase of 98% over the previous quarter.

Further, the firm sold 2,904 kilograms of cannabis, an 8% increase from the previous quarter. Perhaps the most important news Hexo revealed was the closing of its acquisition of Newstrike Brands Ltd in late May. With this deal, Hexo gained access to about 1.8 million square feet of production space and 638,000 square feet of manufacturing and distribution space.

Plans to enter the U.S.

Hexo is finally making a play to enter the U.S market. While the company is still keeping some of the details close to its vest (investors weren’t told which eight U.S states the firm would do business in), Hexo did reveal that it plans on using its partnership with Molson Coors Brewing to start selling CBD derived products in the U.S. As a reminder, the U.S is the largest market in the world. Hexo’s decision to move its operations south of the border is great news for investors.

Strong guidance

Hexo is on track to double its revenues during the next quarter and record a net revenue of $400 million during fiscal year 2020. To do so, the firm will no doubt leverage its increased production capacity (especially now that the Newstrike acquisition is complete), and its numerous distribution channels. These include supply agreements with various Canadian provinces. In particular, the company’s five-year preferred supply agreement with the “Société des alcools du Québec” could generate in excess of $1 billion in revenues over the course of the agreement.

Should you buy?

I don’t believe that Hexo’s latest earnings report changes its fundamental investment thesis. Though the firm might have missed on net revenue estimates, it seems well positioned to take advantage of the upcoming legalization of cannabis-infused products via its partnership with Molson Coors Brewing. Also, the company is planning on entering the U.S market soon, which should raise its profile even more. Coupled with its already relatively strong domestic operations — which should be bolstered by its acquisition of Newstrike — Hexo still looks like an intriguing prospects.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Prosper Bakiny holds shares of Hexo Corp. The Motley Fool owns shares of Molson Coors Brewing.

More on Cannabis Stocks

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Could Double in 2024

Canopy Growth (TSX:WEED) stock saw its share more than double in the last two weeks. So, can it do it…

Read more »

Coworkers standing near a wall
Cannabis Stocks

Why Is Everyone Talking About Canopy Growth Stock?

Canopy Growth stock (TSX:WEED) saw shares surge in the last two weeks for a variety of reasons investors can dig…

Read more »

Pot stocks are a riskier investment
Stocks for Beginners

Why Shares of Cannabis Stocks Are Rising This Week

Cannabis stocks received a boost this week as the White House urged the drug enforcement administration to reschedule the drug.

Read more »

A person holds a small glass jar of marijuana.
Stocks for Beginners

Why Canopy Growth Stock Jumped 16% on Wednesday

Canopy Growth stock (TSX:WEED) is up 16% on Wednesday, adding to a surge of 60% growth in the last week…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Is the Worst Over for Canopy Growth Stock?

Down 99% from all-time highs Canopy Growth stock has burnt investor wealth and remains a high-risk investment.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Steer Clear: This Stock Spells Trouble

A newly listed cannabis stock is outperforming in 2024 but investors should stay clear to avoid trouble and losses.

Read more »

Cannabis stocks have fallen.
Cannabis Stocks

2 Best Marijuana Stocks to Buy This Month

Marijuana stocks in the U.S. such as Green Thumb and Curaleaf can help you deliver outsized gains to investors in…

Read more »